Survival with Cemiplimab in Recurrent Cervical Cancer

Overview of attention for article published in New England Journal of Medicine, February 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 98 news outlets
blogs: 2 blogs
twitter: 50 X users

facebook: 1 Facebook page
guideline: 9 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 265 Mendeley

So far, Altmetric has seen 106 news stories from 98 outlets.

Cemiplimab Recommended for Advanced Cervical Cancer

Medscape, 24 Jun 2026

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab (Libtayo, Regeneron) for adults with…

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma | 2 Minute Medicine

2 Minute Medicine , 24 Jul 2025

1. Progression-free survival was significantly greater in retifanlimab compared to placebo.

Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer

MedPage Today, 06 Nov 2023

Meeting Coverage > IGCS Overall response beats historical benchmark, but misses significance target by Mike Bassett, Staff…

Later-line tisotumab vedotin shows survival benefit in metastatic cervical CA

Pediatric News , 01 Nov 2023

The antibody-drug conjugate tisotumab vedotin bested chemotherapy for the second- or third-line treatment of recurrent/metastatic…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 102 additional news stories.